New Lung Cancer Data May Offer Reprieve For Peregrine’s Bavituximab
This article was originally published in The Pink Sheet Daily
Executive Summary
Company releases new analysis of a Phase II second-line lung cancer study that resolves discrepancies that were holding back regulatory progress, now showing a 4.4 month overall survival benefit for first-in-class bavituximab. Peregrine is now gearing up for a Phase III study at the end of 2013.